Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects
/PRNewswire/ -- Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data...
Source: prnewswire.com